SCHEMBL7193441

SCHEMBL7193441

NC(C=O)c1ccc(O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 7/20 0.42
ESR2 Q92731 6/20 0.42
PDCD1 Q15116 1/20 0.42
CD274 Q9NZQ7 1/20 0.42
ALDH5A1 P51649 1/20 0.42
ABAT P80404 1/20 0.42
HIF1A Q16665 3/20 0.41
TAAR1 Q96RJ0 2/20 0.41
NFKB1 P19838 2/20 0.41
HTR3A P46098 1/20 0.41
TSHR P16473 1/20 0.41
ALOX15 P16050 4/20 0.40
KDM4E B2RXH2 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
APEX1 P27695 1/20 0.40
MAPT P10636 3/20 0.38
CYP3A4 P08684 3/20 0.38
ALDH1A1 P00352 3/20 0.38
LMNA P02545 2/20 0.38
CA3 P07451 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12871736 1.00 ESR1 (0.42) ESR1ESR2PDCD1CD274ALDH5A1
Hydrochloric Acid SCHEMBL13738816 0.85 TYR (0.33) TYR
Hydrochloric Acid SCHEMBL2035158 0.78 DRD1 (0.32) TYRDRD1
Hydrochloric Acid SCHEMBL3388587 0.78 DRD1 (0.32) TYRDRD1
SCHEMBL4736322 0.76 ADRB2 (0.50) HIF1ANFKB1TSHRTDP1CYP3A4
SCHEMBL540045 0.76 HTR2A (0.39) ALOX15ALDH1A1MEN1CA2KMT2A
SCHEMBL13131486 0.76 IDO1 (0.43) ALDH1A1LMNAIDO1TDO2
SCHEMBL3526327 0.76 ESR1 (0.42) ESR1ESR2PDCD1CD274ALDH5A1
SCHEMBL20495038 0.76 IDO1 (0.43) ALDH1A1LMNAIDO1TDO2
SCHEMBL6498253 0.76 IDO1 (0.43) ALDH1A1LMNAIDO1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2377528-A2 Fatty acid metabolism inhibitors for use in the treatment of cancer The Board of Regents of the University of Colorado (US) 2011-10-19 EP disclosed
US-6566355-B1 Useful in combination with beta -lactam antibiotics in the control of beta -lactamase forming pathogens HOFFMANN-LA ROCHE INC. 2003-05-20 US disclosed
US-5712268-A Compositions of tricyclic β-lactams and uses thereof HOFFMANN-LA ROCHE INC. (US) 1998-01-27 US disclosed
US-5698577-A ANTIBIOTICS HOFFMANN-LA ROCHE INC. (US) 1997-12-16 US disclosed
EP-0508234-B1 Beta-lactames HOFFMANN LA ROCHE (CH) 1996-07-24 EP disclosed
US-5510343-A BETA-LACTAMASE INHIBITOR HOFFMANN-LA ROCHE INC. (US) 1996-04-23 US disclosed
EP-0508234-A2 Beta-lactames F. HOFFMANN-LA ROCHE AG (CH) 1992-10-14 EP disclosed
EP-0006712-A1 Heterocyclic derivatives of (4-aryloxymethyl-1.3-dioxolan-2-yl) methyl-1H-imidazoles and -1H-1.2.4-triazoles, their preparation and the derivatives for use as fungicides and bactericides JANSSEN PHARMACEUTICA N.V. (BE) 1980-01-09 EP disclosed